Here "causes" refers mainly to why a patient may need a stem cell transplant-the underlying diseases and clinical situations-and "risk" refers to both who is likely to be considered for transplant and the risks associated with the procedure itself.

Why patients may need a stem cell transplant

The most common indications include:

1. Blood cancers (hematologic malignancies)

   1. Acute leukemias (AML, ALL)

   2. Chronic leukemias (CML, advanced CLL)

   3. Lymphomas (Hodgkin and non-Hodgkin)

   4. Multiple myeloma and related plasma cell disorders

2. Non-malignant bone marrow disorders

   1. Severe aplastic anemia

   2. Myelodysplastic syndromes

   3. Myeloproliferative neoplasms

   4. Congenital marrow failure syndromes

3. Inherited or acquired immune deficiencies and metabolic diseases

   1. Severe combined immunodeficiency (SCID)

   2. Certain inborn errors of metabolism (e.g., some lysosomal storage diseases)

   3. Hemoglobinopathies such as sickle cell disease and thalassemia - where allogeneic HSCT can now offer a genuine cure in carefully selected patients.

In many of these conditions, standard chemotherapy or immunosuppression alone is unlikely to provide durable control or cure. HSCT is considered when the expected benefit in survival or quality of life outweighs the short- and long-term risks.

Who is more likely to be offered stem cell transplantation?

Patients are more likely to be candidates for HSCT if they:

1. Have a disease with high risk of relapse or poor prognosis using standard therapy alone.

2. Are fit enough (cardiac, lung, kidney, liver function) to tolerate intensive treatment.

3. Have an appropriate stem cell source: their own cells (auto-HSCT) or a suitably matched donor (allo-HSCT).

4. Have no uncontrolled infections and acceptable performance status.

Risks associated with undergoing stem cell transplantation

HSCT is associated with significant treatment-related risk, especially in allogeneic procedures:

1. Short-term risks

   1. Severe infections during the period of low white blood cells

   2. Organ toxicities from chemotherapy/radiation (heart, lungs, liver, kidneys)

   3. Graft failure (failure of donor cells to engraft)

2. Allogeneic-specific risks

   1. Graft-versus-host disease (GVHD), where donor immune cells attack the recipient's tissues, a major source of morbidity and mortality and responsible for up to ~20% of deaths in some cohorts.

3. Long-term risks

   1. Secondary cancers, endocrine and metabolic complications, cardiovascular disease, chronic infections and reduced life expectancy compared with the general population.

Because of these risks, transplant centres use detailed scoring systems and multi-disciplinary discussions to balance the risk of the disease against the risk of the transplant for each patient.

Strictly speaking, "symptoms and signs" belong to:

1. The underlying disease that leads to transplant, and

2. The transplant journey itself - what patients experience during and after HSCT.

Before transplant - symptoms of diseases that may need HSCT

Patients who eventually undergo stem cell transplantation typically have symptoms related to their original illness, such as:

1. Anemia - fatigue, paleness, breathlessness

2. Frequent or severe infections due to low white cells

3. Easy bruising or bleeding from low platelets

4. Bone pain, night sweats, weight loss or fevers in leukemias/lymphomas

5. Pain crises and organ damage in diseases like sickle cell disease

These symptoms often persist or recur despite standard treatments, prompting evaluation for HSCT as the next step.

Around the time of transplant - expected experiences

During the transplant process, patients go through several well-defined phases:

1. Conditioning phase - high-dose chemotherapy, sometimes with radiation, to eradicate disease and suppress the immune system.

   1. Common symptoms: nausea, vomiting, diarrhoea, mouth sores (mucositis), hair loss, profound fatigue and increased infection risk.

2. Engraftment phase - after the stem cells are infused, blood counts initially drop very low before slowly recovering as the graft "takes".

   1. Symptoms: extreme tiredness, susceptibility to infections, need for transfusions, sometimes fevers or chills.

3. Early recovery - as counts recover, some symptoms improve, but patients may still feel weak, short of breath on exertion, or "not themselves".

In allogeneic transplants, early or acute GVHD can cause:

1. Red, itchy rash; peeling skin

2. Nausea, vomiting, abdominal pain, diarrhoea

3. Jaundice or abnormal liver tests

Later, chronic GVHD can mimic autoimmune disease, affecting skin, eyes, mouth, lungs and other organs.

Clear explanations about these phases help patients and families recognise what is expected and what needs urgent medical attention.

In practice, we don't "diagnose stem cell transplantation"; we diagnose the underlying condition, then determine whether HSCT is indicated and feasible.

Diagnostic work-up of the underlying disease

This includes disease-specific investigations such as:

1. Blood tests and bone marrow examination - morphology, flow cytometry, cytogenetics and molecular markers in leukemias and marrow disorders.

2. Imaging - CT, PET-CT or MRI for lymphomas and solid tumours.

3. Specific functional tests for immune deficiencies or metabolic disorders.

Assessing suitability for transplant

Once the disease is characterised and staged, transplant physicians perform a detailed pre-transplant evaluation:

1. Performance status and organ function - heart echocardiogram, lung function tests, liver and kidney function, infection screening.

2. Comorbidity scores and risk indexes to estimate transplant-related mortality.

3. Donor search and HLA typing - to identify a suitable related or unrelated donor, or to collect the patient's own stem cells in autologous procedures.

Planning the type of transplant

The team decides:

1. Autologous vs allogeneic transplant

   1. Autologous: patient's own stem cells are collected in advance, stored, and returned after high-dose chemotherapy (common in multiple myeloma and some lymphomas).

   2. Allogeneic: donor stem cells are used; chosen when a graft-versus-tumour/ malignancy effect is desired or when the underlying marrow is fundamentally abnormal (e.g., aplastic anemia, many leukemias, sickle cell disease).

2. Conditioning intensity

   1. Myeloablative regimens for younger, fitter patients.

   2. Reduced-intensity regimens to allow older or more fragile patients to undergo transplant with lower toxicity, relying more on immune-mediated graft-versus-disease effects.

All these decisions are individualised and discussed thoroughly with the patient and family.

This section describes where stem cells come from, how the procedure is done, and emerging alternatives/adjuncts.

Main types of stem cell transplant

1. Autologous stem cell transplantation (Auto-HSCT)

   1. Stem cells are collected from the patient's bloodstream, frozen, and re-infused after high-dose chemotherapy.

   2. Used widely in multiple myeloma and certain lymphomas to allow chemotherapy doses that would otherwise permanently damage the bone marrow.

   3. Advantages: no risk of GVHD, lower early transplant-related mortality; disadvantages: risk of disease relapse remains, as there is no graft-versus-tumour effect.

2. Allogeneic stem cell transplantation (Allo-HSCT)

   1. Stem cells come from a matched sibling, matched unrelated donor, partially matched (haploidentical) family member, or umbilical cord blood.

   2. Provides healthy stem cells and a graft-versus-malignancy effect, in which donor immune cells attack residual cancer cells, lowering relapse risk.

   3. Disadvantages: higher risk of GVHD, infections and non-relapse mortality, especially in the first 100 days.

3. Sources of stem cells

   1. Peripheral blood stem cells (PBSC) - most common today; collected by apheresis after growth factor mobilisation.

   2. Bone marrow - harvested directly from donor's hip bones in theatre.

   3. Umbilical cord blood - rich in stem cells and more tolerant of HLA mismatch, but limited cell dose can slow engraftment, especially in adults.

How the transplant is performed - overview

1. Conditioning - chemotherapy ± radiation to eradicate disease and suppress immunity.

2. Stem cell infusion - stem cells are given through a vein, similar to a blood transfusion.

3. Engraftment and supportive care - transfusions, antibiotics, antifungals and antivirals, nutritional and psychological support.

Relationship to other advanced therapies

The role of HSCT is evolving with the rise of CAR T-cell therapy and other cellular immunotherapies:

1. In some lymphomas and leukemias, CAR T-cell therapy can achieve high remission rates and may be used instead of, or before, transplantation.

2. In other settings, particularly high-risk acute leukemia, patients may receive CAR T therapy to achieve remission, followed by allogeneic HSCT as a consolidation to improve long-term disease control.

Transplant teams now routinely discuss these options in multidisciplinary tumour boards to choose the most suitable sequence for each patient.

Here we focus on preventing complications and optimising long-term health in transplant candidates and survivors.

Preventing complications around the time of transplant

Key strategies include:

1. Rigorous infection prevention

   1. Protective isolation, hand hygiene, HEPA-filtered rooms in some centres

   2. Prophylactic antibiotics, antifungals and antivirals while counts are low.

2. Modern GVHD prophylaxis in allogeneic HSCT

   1. Traditional calcineurin inhibitor-based regimens plus methotrexate or mycophenolate.

   2. Newer approaches, such as post-transplant cyclophosphamide with a calcineurin inhibitor, which have improved GVHD-free, relapse-free survival in recent trials.

3. Organ protection and supportive care

   1. Careful choice and dosing of conditioning regimens

   2. Aggressive management of mucositis, nausea, nutrition and fluid balance

   3. Close monitoring for heart, lung, liver or kidney stress.

Long-term prevention and survivorship management

Transplant survivors require structured lifelong follow-up, because late effects can emerge years after HSCT:

1. Regular screening for:

   1. Secondary cancers, especially skin, oral and solid organ malignancies

   2. Cardiovascular risk factors (blood pressure, lipids, diabetes)

   3. Endocrine issues (thyroid, adrenal, pituitary function), bone health and fertility

   4. Chronic infections and vaccine responses

2. Counselling on lifestyle factors - smoking cessation, healthy diet, exercise, sun protection, safe sexual practices and vaccinations - to reduce the burden of late complications.

Multidisciplinary survivorship programs now emphasise not only medical monitoring but also psychological, social and vocational support, recognising that many survivors face work limitations, anxiety and other psychosocial challenges.

Complications can be acute (early) or chronic (late) and vary by transplant type.

Early complications

1. Infections - bacterial, viral and fungal infections are the leading causes of early morbidity and mortality while blood counts and immunity are low.

2. Graft failure - failure of donor cells to engraft, requiring rescue strategies and associated with high risk.

3. Organ toxicity - heart failure, lung injury (e.g., diffuse alveolar damage), liver problems (veno-occlusive disease), kidney injury.

4. Acute GVHD (allogeneic) - usually within the first 100 days, primarily affecting skin, gut and liver; can be mild or life-threatening.

Late complications

Even years after transplant, survivors may experience significant late effects:

1. Chronic GVHD - may involve skin, eyes, mouth, lungs, joints and other organs, resembling autoimmune disease; a major cause of long-term morbidity.

2. Secondary malignancies - solid tumours and therapy-related leukemias, a leading cause of late deaths among long-term survivors.

3. Metabolic and endocrine complications - growth and pubertal issues in children, thyroid dysfunction, diabetes, dyslipidemia, osteoporosis, infertility.

4. Cardiovascular and pulmonary disease - accelerated atherosclerosis, cardiomyopathy, restrictive or obstructive lung disease.

5. Neurocognitive and psychosocial issues - fatigue, depression, anxiety, cognitive changes and reduced work capacity.

Despite these complications, studies show that patients who are disease-free at 2-5 years after HSCT often have an >80% chance of surviving at least another 10 years, although their life expectancy remains somewhat lower than the general population.

Early recovery and rebuilding daily life

After discharge, many patients are surprised by how long recovery can feel:

1. Persistent fatigue, reduced stamina and emotional ups and downs are common for months.

2. Frequent clinic visits for blood tests, transfusions, infection monitoring and immunosuppressive drug adjustments are routine, especially after allogeneic HSCT.

3. Patients are usually advised to avoid crowded places, sick contacts, raw foods and unsafe water until their immune system recovers.

Gradually, as blood counts stabilise and immunosuppression is tapered, people return to work or study, resume social activities and rebuild their routines.

Long-term survivorship and quality of life

The number of long-term HSCT survivors is growing rapidly worldwide, creating a new population with unique needs.

Key aspects of living well after transplant include:

1. Regular survivorship clinic visits - with a transplant team or knowledgeable primary care provider who understands HSCT-specific late effects and screening recommendations.

2. Vaccination schedules - re-immunisation against childhood diseases, influenza, pneumococcus and other infections once the immune system is ready.

3. Psychological support - coping with fear of relapse, body image changes, fertility concerns and workplace reintegration.

4. Healthy lifestyle - exercise, weight management, smoking cessation and heart-healthy diet to offset increased cardiovascular risk.

Many survivors describe the transplant journey as both challenging and life-changing. With appropriate medical follow-up, family support and rehabilitation, a large proportion are able to return to meaningful, productive lives, even while managing some chronic effects.

1. What is stem cell transplantation?

Stem cell transplantation (often called bone marrow transplant or hematopoietic stem cell transplant) is a procedure in which a patient receives healthy blood-forming stem cells to replace bone marrow that has been damaged or destroyed by disease, high-dose chemotherapy, or radiation. These stem cells can come from the patient themselves (autologous), a matched donor (allogeneic), or an identical twin (syngeneic). Once infused into a vein, the cells travel to the bone marrow, where they engraft and start making new red blood cells, white blood cells, and platelets, rebuilding the blood and immune system. 

---

2. Which diseases are treated with stem cell transplantation?

Stem cell transplantation is mainly used for blood and bone-marrow disorders and some immune conditions. Common indications include leukemias (acute and chronic), lymphomas, multiple myeloma, myelodysplastic syndromes, and some childhood cancers like neuroblastoma and Ewing sarcoma. It is also used for serious non-cancer conditions such as aplastic anemia, thalassemia, sickle cell disease, certain inherited immune deficiencies, and some severe autoimmune diseases when other treatments fail. Because it is an intensive therapy with its own risks, doctors usually reserve it for life-threatening or high-risk diseases where the potential benefit is substantial. 

---

3. What are the main types of stem cell transplants?

There are three major types:

1. Autologous transplant - the patient's own stem cells are collected in advance, stored, and later returned after high-dose chemotherapy. This avoids donor-immune reactions and is common in multiple myeloma and some lymphomas.

2. Allogeneic transplant - stem cells come from another person: a sibling, family member, or unrelated volunteer donor whose tissue type (HLA) closely matches the patient. Here, the new immune system can also attack remaining cancer cells (graft-versus-tumor effect) but may cause graft-versus-host disease (GVHD).

3. Syngeneic transplant - from an identical twin, which provides perfect matching and low rejection risk, but is rare.

Doctors choose the type based on the disease, patient's age and health, availability of a donor, and whether using the patient's own cells would risk re-introducing cancer.

---

4. How does the stem cell transplant process work?

Although details vary by center, the process usually includes:

1. Pre-transplant evaluation - detailed tests of the heart, lungs, kidneys, and overall health, plus disease staging.

2. Stem cell collection - stem cells are obtained from blood, bone marrow, or umbilical cord blood. Today, most are collected from the blood after giving injections that "mobilize" stem cells out of the marrow.

3. Conditioning (pre-transplant treatment) - high-dose chemotherapy, often with or without total body irradiation, to destroy cancer cells, suppress the immune system, and make space in the marrow for new cells. 

4. Stem cell infusion - the collected cells are infused through a vein, similar to a blood transfusion; this part itself is usually painless.

5. Engraftment and recovery - over 2-4 weeks (longer for cord blood), the transplanted cells settle in the bone marrow and start producing new blood cells. During this phase the patient is very vulnerable to infection, bleeding, and other complications and is closely monitored in hospital.

---

5. What are the risks and side effects of stem cell transplantation?

Stem cell transplantation is a high-risk, high-benefit treatment. Short-term effects come mainly from the conditioning therapy and the early engraftment phase and can include severe infections, bleeding, mouth and gut sores (mucositis), nausea, hair loss, organ toxicity, and profound fatigue. 

Allogeneic transplants can also cause graft-versus-host disease (GVHD), where donor immune cells attack the patient's skin, gut, liver, or other organs, leading to rashes, diarrhea, liver problems, and chronic health issues if not controlled. Long-term risks may include reduced fertility, endocrine problems, cataracts, bone thinning, secondary cancers, and persistent immune deficiency. The likelihood and severity of side effects depend on age, overall health, disease status, transplant type, and the intensity of the preparative regimen. 

---

6. How long does it take to recover after a stem cell transplant?

Recovery is a long journey, not a single event. Blood counts usually start to recover within 2-3 weeks for blood or bone marrow transplants and 3-5 weeks for cord blood transplants, but immune recovery continues for months. 

Broadly:

1. After autologous transplant, many patients feel substantially better in about 2-3 months, though some fatigue may linger longer.

2. After allogeneic transplant, full immune and functional recovery can take 6-18 months or more, especially if GVHD or infections occur. 

During early recovery, you may need to stay near the transplant center, follow strict infection-prevention measures, attend frequent check-ups, and receive transfusions, antibiotics, and supportive care until your new marrow is working reliably.

---

7. What is graft-versus-host disease (GVHD) and why is it important?

GVHD is a complication of allogeneic transplants. Because the donor's immune cells view the patient's body as foreign, they can attack organs such as the skin, intestines, and liver.

1. Acute GVHD usually occurs in the first weeks to months and often causes skin rashes, diarrhea, abdominal pain, and liver test abnormalities.

2. Chronic GVHD appears later and may affect many organs, causing dry eyes and mouth, skin tightening, lung problems, and fatigue. 

GVHD is treated and prevented with immunosuppressive drugs. A mild graft-versus-host reaction can sometimes be beneficial because it is linked to the graft-versus-tumor (or leukemia) effect, where donor immune cells also attack remaining cancer cells. The challenge for doctors is balancing enough immune activity to fight disease but not so much that it seriously harms the patient. 

---

8. How is a stem cell donor chosen and what does donation involve?

For an allogeneic transplant, doctors search first among brothers and sisters for an HLA-matched donor. If none is suitable, they look for a matched unrelated donor in international registries or consider haploidentical (half-matched) family donors or cord blood units. Matching reduces the risk of rejection and GVHD. 

Donation itself is usually done by:

1. Peripheral blood stem cell collection - the donor receives a few days of injections to mobilize stem cells into the blood, then spends several hours connected to an apheresis machine that collects stem cells and returns the rest of the blood.

2. Less commonly, bone marrow harvest under anesthesia, where liquid marrow is taken from pelvic bones with needles. 

Most donors recover quickly, with temporary side effects such as bone pain or fatigue. Long-term serious complications for healthy donors are rare.

---

9. Can stem cell transplantation cure cancer or blood diseases?

For some conditions, a stem cell transplant offers a real chance of cure or very long-term remission. In high-risk leukemias, lymphomas, and certain inherited blood disorders, it may eliminate diseased cells and replace them with a healthy blood-forming system, especially when combined with a strong graft-versus-tumor effect from a donor graft.

However, success depends on many factors: type and stage of disease, response to previous treatment, patient age and fitness, transplant type, and whether complications occur. In some situations, transplant is used not with curative intent but to prolong survival, reduce symptoms, or control disease when other options are limited. Your transplant team will usually discuss estimated cure or remission rates based on large studies and your individual risk profile.

---

10. What questions should patients and families ask before deciding on stem cell transplantation?

Because stem cell transplantation is a complex and intensive therapy, it's vital to have an open discussion with the transplant team. Helpful questions include:

1. Why are you recommending a transplant in my case? Are there other effective options?

2. Which type of transplant (autologous or allogeneic) is planned, and why?

3. What is my chance of cure or long-term control with and without transplant?

4. What are the short-term and long-term risks, including GVHD, infections, fertility issues, and late effects? 

5. How long will I need to stay in or near the hospital, and what will day-to-day life look like during recovery? 

6. How will this affect my work, family responsibilities, finances, and quality of life in the first year?

7. What support services (nutrition, psychology, social work, physiotherapy) are available for me and my family?

Clear answers to these questions help patients and caregivers make an informed decision and prepare practically and emotionally for the transplant journey.